
So far only one potential malaria vaccine, developed by GlaxoSmithKline, has reached clinical trial phase III. But now a Danish developed vaccine candidate is on the verge of joining that exclusive company.
Behind the vaccine is senior researcher Michael Theisen from Statens Serum Institute (SSI), who has spent the last roughly 20 years driving research to the current stage, where a clarification of the ongoing phase II trials is expected within six months.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app